Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsors and Collaborators: |
Baylor College of Medicine Eli Lilly and Company TAP Pharmaceutical Products Inc. |
---|---|
Information provided by: | Baylor College of Medicine |
ClinicalTrials.gov Identifier: | NCT00206375 |
The purpose of this study is to see if giving growth hormone and Lupron along with thyroid hormone will improve final height in patients with long term hypothyroidism. Lupron is a medicine which is used to delay puberty and to prevent early closure of growing bones which might increase growth potential. Growth hormone is used to restore growth rate. This study will include children with "short term" and "long term" hypothyroidism.
Condition | Intervention | Phase |
---|---|---|
Hypothyroidism |
Drug: Growth hormone Drug: Growth hormone treatment and puberty |
Phase IV |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Open Label, Active Control, Single Group Assignment, Efficacy Study |
Official Title: | Concomitant Use of Growth Hormone and GnRH Agonist in Adolescent Patients With Acquired Hypothyroidism |
Estimated Enrollment: | 21 |
Study Start Date: | May 2003 |
Estimated Study Completion Date: | March 2012 |
Estimated Primary Completion Date: | March 2012 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
1: No Intervention
Synthroid alone
|
|
2: Experimental
Growth hormone + synthroid + lupron
|
Drug: Growth hormone
Growth hormone + Synthroid + Lupron
Drug: Growth hormone treatment and puberty
Lupron once a month and growth hormone daily
|
3: No Intervention
Acute hypothyroidism
|
Hypothyroidism is often associated with growth failure. It takes several years for slow growth to be noticed. This growth retardation is typically severe and progressive.
Thyroid hormone is necessary for normal growth. Treatment with thyroxine (thyroid hormone) results in rapid catch-up growth, which mostly happens during the first 18 months. Growth is accompanied by increased bone age, which means early fusion (closure of the growing bones) of the bones and reduced growth potential. For example, a patient, who is 10 years old but has bone age of 12 years, has growth potential of a 12 year old and will stop growing 2 years earlier than a 10 year old patient. According to the literature, prolonged juvenile hypothyroidism (low thyroid condition) resulted in a permanent loss in height and only 70% catch-up growth was generally achieved with thyroxine replacement.
Ages Eligible for Study: | 8 Years to 17 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
Exclusion Criteria:
Contact: Kimberly Mason, RN | 832-822-1010 | kjmason@bcm.tmc.edu |
United States, Texas | |
Baylor college of Medicine | Recruiting |
Houston, Texas, United States, 77030 | |
Contact: Lori Malone 832-822-3784 lcmalone@texaschildrenshospital.org |
Principal Investigator: | Parvin Yazdani, MD | Baylor College of Medicine |
Responsible Party: | Baylor College of Medicine ( Parvin Yazdani, MD ) |
Study ID Numbers: | H-13213 |
Study First Received: | September 13, 2005 |
Last Updated: | July 16, 2008 |
ClinicalTrials.gov Identifier: | NCT00206375 |
Health Authority: | United States: Institutional Review Board |
Hypothyroidism Growth hormone |
Deslorelin Leuprolide Endocrine System Diseases |
Hypothyroidism Endocrinopathy Thyroid Diseases |